Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A new Locations section lists Charlottesville, Virginia as a study site. The page revision is updated to v3.3.3, and the prior Virginia Locations entry and the HHS Vulnerability Disclosure link were removed.
    Difference
    0.2%
    Check dated 2025-12-23T08:58:52.000Z thumbnail image
  4. Check
    24 days ago
    No Change Detected
  5. Check
    38 days ago
    Change Detected
    Summary
    The page footer now displays a revision update from v3.3.1 to v3.3.2. This update does not modify substantive content or user-facing features.
    Difference
    0.1%
    Check dated 2025-12-01T16:49:53.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.1; no substantive study content changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T13:27:57.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The funding-status notice about government funding and site operations has been removed. The study details remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-17T06:29:50.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    New screenshot shows the same Study Details page with minor layout and styling changes; core study information such as eligibility criteria, locations, and outcomes remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T01:10:47.000Z thumbnail image
  9. Check
    95 days ago
    Change Detected
    Summary
    Upgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.
    Difference
    4%
    Check dated 2025-10-05T09:55:44.000Z thumbnail image

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.